Last June JAMA Internal Medicine published an excellent systematic review and meta-analysis of clinical trials of sublingual immunotherapy for grass pollen allergy [1]. The team of Di Lorenzo of the University of Palermo reached an important result indicating a small, unimpressive effect of sublingual immunotherapy. These findings probably justify no longer this kind of intervention to be paid by any European health care system. Accordingly, the Editor of JAMA has thrown a “caveat emptor” [2] that is similar to a scream towards public welfare managers.
